

THE CHALLENGE: CONDITION RECOGNITION "GAP"

<p>Diabetes mellitus (DM)</p> <p>30.3 million Americans have DM, another 84.1 million have prediabetes.¹ Prevalence 65+ years 25.2%, or 12 million seniors (diagnosed & undiagnosed).²</p>	<p>Chronic kidney disease (CKD)</p> <p>39.4% of people age 60 and older have CKD.³</p>	<p>Peripheral arterial disease (PAD)</p> <p>Although more than half of patients with PAD in one study had leg symptoms, relatively few had classic claudication.⁴ It is estimated that only 25% of afflicted individuals receive care.⁵</p>
---	--	--

Documentation tips and tools:

For patients age 65 and older, use of a **Clinical Testing Flow Sheet** (see back of this sheet) will facilitate capture of dates and results of the following:

- **Blood pressure, weight and BMI (every visit):** "Adults with treated or untreated BP > 135/80 mm Hg should be screened for diabetes." (USPSTF Recommendation)
- **Ankle-brachial index (ABI):** Ankle-brachial index below 0.9 some arterial disease, less than 0.5 severe arterial disease.⁶
- **Comprehensive dilated eye exam:** Recommended annually for patients with diabetes; type 1 begin within 5 years of initial diagnosis; type 2 begin soon after the diagnosis.⁷
- **Comprehensive foot exam:** Foot exam includes inspection, palpation of pedal pulses, testing to detect loss of protective sensation (LOPS). Recommended at least annually.⁷ A peripheral neuropathy screening tool can be obtained from your Optum Healthcare Advocate.
- **Testing for diabetes:**^{7*}
 1. People with one or more high-risk foot conditions should have a visual inspection of their feet at every clinic visit.⁸
 2. A1C ≥ 6.5%. "The test should be performed in a laboratory using a method that is NGSP-certified and standardized to the DCCT assay." Use of the A1C to diagnose diabetes may not be valid with certain clinical conditions.
 3. Fasting (8 hours): FPG ≥ 126mg/dl
 4. Oral glucose tolerance test (OGTT): Plasma glucose ≥ 200mg/dl 2 hr after 75 gm glucose load
 5. Random plasma glucose ≥ 200 mg/dl in patients with classic hyperglycemic symptoms
- **Monitoring glucose control with hemoglobin A1C:**⁷
 - Every 3 months: if modifying therapy or if not meeting glycemic goals
 - Twice a year: if meeting treatment goals and stable glycemic control
- **Diabetic nephropathy screening:** Screen for diabetic nephropathy by testing annually for urine albumin excretion and by determining, at least annually, serum creatinine and estimated GFR.⁷
- **Fasting lipid profile (at least annually):**⁷
 - Without overt CVD, LDL-C goal <100mg/dl
 - With overt CVD, LDL-C goal of <70mg/dl (using high dose of a statin) is an option[†]

For patients who have been recently diagnosed with diabetes, were determined to be at risk for complications from diabetes, or were previously diagnosed with diabetes before meeting Medicare eligibility requirements, effective January 1, 2011, individual and group diabetes self-management training (DSMT) services are reportable (HCPCS codes G0108 & G0109).¹¹ For more information, see:

www.cms.gov/Medicare/Prevention/PrevntionGenInfo/Medicare-preventive-services/IMPS-QuickReferenceChart-1.html

* In the absence of unequivocal hyperglycemia, "Testing for Diabetes" criteria 1 – 3 should be confirmed by repeat testing.

† Statin contraindicated in pregnancy

ICD-10-CM CODING GUIDE⁹

Diabetes* (partial listing)	
Type 2 Diabetes with complications:	
<i>Note: Assign as many E11.- codes as needed to identify all the manifestations</i>	
Type 2 diabetes mellitus with diabetic nephropathy	E11.21
Type 2 diabetes mellitus with diabetic chronic kidney disease <i>Use additional code to identify stage of chronic kidney disease (N18.1-N18.6)</i>	E11.22
Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema (<i>code type of retinopathy, if known, and laterality</i>)	E11.311
Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema (<i>code type of retinopathy, if known, and laterality</i>)	E11.319
Type 2 diabetes mellitus with diabetic cataract	E11.36
Type 2 diabetes mellitus with diabetic neuropathy, unspecified	E11.40
Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	E11.51**
Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	E11.52**
Type 2 diabetes mellitus with foot ulcer <i>Use additional code to identify site of ulcer (L97.4-, L97.5-)</i>	E11.621
Type 2 diabetes mellitus with hypoglycemia without coma	E11.649
Type 2 diabetes mellitus with hyperglycemia	E11.65
Type 2 diabetes mellitus with other specified complication <i>Use additional code to identify complication</i>	E11.69
Type 2 diabetes mellitus without complications	E11.9
<i>*Use additional code to identify control using: insulin (Z79.4), oral antidiabetic drugs (Z79.84) or oral hypoglycemic drugs (Z79.84).</i>	
<i>**Use an additional code to provide additional details of atherosclerosis of native arteries of extremities such as laterality and manifestations, if applicable.</i>	
Chronic kidney disease*	
GFR value = mL/min/1.73 m ²	
CKD is defined as either kidney damage or GFR < 60mL/min/1.73 m ² for ≥ 3 months. ¹⁰	
Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests (for example, untimed spot urine albumin/creatinine ratio or microalbumin-sensitive dipstick) or imaging studies. ¹⁰	
Stage 1: GFR ≥ 90 with kidney damage	N18.1
Stage 2: GFR 60–89 with kidney damage	N18.2
Stage 3: GFR 30–59	N18.3
Stage 4: GFR 15–29	N18.4
Stage 5: GFR less than 15 (if stage 5 requiring chronic dialysis, N18.6)	N18.5
ESRD: requiring chronic dialysis or transplantation	N18.6
Chronic kidney disease, unspecified	N18.9
<i>*Use additional code to identify kidney transplant status (Z94.0), renal dialysis status (Z99.2) or noncompliance with renal dialysis (Z91.15), if applicable.</i>	
Peripheral arterial disease (partial listing)	
Peripheral arterial disease NOS	I73.9
Peripheral vascular disease NOS	
Intermittent claudication NOS	
Atherosclerosis/Arteriosclerosis of native arteries of the extremities:	
with intermittent claudication	I70.21-*
with rest pain	I70.22-*
right leg with ulceration	I70.23-**
left leg with ulceration	I70.24-**
with gangrene	I70.26-**
unspecified	I70.20-*
Atherosclerosis of bypass graft of the extremities, unspecified graft	I70.30-*
<i>*6th characters 1, 2 and 3 represent right, left and bilateral respectively.</i>	
<i>**Use additional code to identify severity of ulcer (L97.-, L98.49-), if applicable. Additional characters in L97.- report site, laterality (e.g. right, left) and severity.</i>	
<i>Use additional code, if applicable, to identify chronic total occlusion of artery of extremity (I70.92).</i>	

Clinical testing flow sheet

PATIENT NAME _____

MEDICAL RECORD # _____

SERVICE OR TEST	✓ done in 2019	date _____	date _____	date _____	date _____
EXAMINATION					
BLOOD PRESSURE					
WEIGHT/BMI					
ANKLE-BRACHIAL INDEX					
DILATED EYE EXAM					
FOOT EXAM					
PEDAL PULSES					
VISUAL EXAM					
VIBRATION/REFLEXES					
LABORATORY TESTING					
BLOOD GLUCOSE					
FASTING					
RANDOM					
A1C					
URINE FOR ALBUMIN					
URINE ALBUMIN TO CR					
CALCULATED GFR					
LIPID PROFILE					
TOTAL CHOLESTEROL					
TRIGLYCERIDES					
HDL CHOLESTEROL					
LDL CHOLESTEROL					

Per the ICD-10-CM Official Guidelines for Coding and Reporting FY 2019: "A dash (-) at the end of an alphabetic index entry indicates that additional characters are required. Even if a dash is not included at the alphabetic index entry, it is necessary to refer to the tabular list to verify that no 7th character is required." The bolding of the ICD-10-CM codes represents categories, subcategories or codes that map to the CMS-HCC risk adjustment model for payment year 2019.

1. <https://www.cdc.gov/diabetes/basics/quick-facts.html>, Page last updated: May 11, 2018, Content source: HYPERLINK "http://www.cdc.gov/" Centers for Disease Control and Prevention
2. <http://www.diabetes.org/diabetes-basics/statistics/last%20edited%20March%202022> http://www.diabetes.org/diabetes-basics/statistics/last edited March 22, 2018
3. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291282/>
4. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al., "Peripheral arterial disease detection, awareness, and treatment in primary care." *JAMA* 286(2001): 1317-24.
5. Heart Association Statistics Committee and Stroke Statistics Subcommittee, "Heart Disease and Stroke Statistics." *Circulation* 117(2008): e25-e146.
6. ACC/AHA, "Guidelines for the Management of Patients With Peripheral Arterial Disease." *Journal of American College of Cardiology* 47(2006): e1-e192. <http://www.aafp.org/afp/2013/0901/p306.html>
7. American Diabetes Association: "Standards of Medical Care in Diabetes -- 2010," *Diabetes Care*, January 2010; vol 33: supplement 1.
8. Standards of Medical Care in Diabetes—2011 *Diabetes Care* January 2011. vol. 34 no. Supplement 1 S4-S10 Singh N, Armstrong DG, et al.
9. Optum360 ICD-10-CM: Professional for Physicians 2019. Salt Lake City, UT: 2018.
10. National Kidney Foundation, "KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification." *American Journal of Kidney Disease* 39: 2002 supplement 1.
11. Optum360 2019 HCPCS Level II Professional. Salt Lake City, UT: Optum360; 2018. https://www.cms.gov/Medicare/Prevention/PreventionGenInfo/medicare-preventive-services/MPS-QuickReferenceChart-1.html#DIABETES_SELF



This guidance is to be used for easy reference; however, the ICD-10-CM code book and the Official Guidelines for Coding and Reporting are the authoritative references for accurate and complete coding. The information presented herein is for general informational purposes only. Neither Optum nor its affiliates warrant or represent that the information contained herein is complete, accurate or free from defects. Specific documentation is reflective of the "thought process" of the provider when treating patients. All conditions affecting the care, treatment or management of the patient should be documented with their status and treatment, and coded to the highest level of specificity. Enhanced precision and accuracy in the codes selected is the ultimate goal. Lastly, on April 2, 2018, the Centers for Medicare & Medicaid Services (CMS) announced that 2018 dates of service for the 2019 payment year model are based on 100% of the 2019 CMS-HCC model mappings released April 2, 2018. See: <https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2019.pdf>

Optum® is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other brand or product names are the property of their respective owners. This document is proprietary and confidential; altering, rebranding, public posting and/or digital downloading is not permitted without the express consent of Optum. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer.